Literature DB >> 8980399

MYCL genotypes and loss of heterozygosity in non-small-cell lung cancer.

K M Fong1, Y Kida, P V Zimmerman, P J Smith.   

Abstract

Some studies have suggested that the S allele of the MYCL oncogene, which results from an intragenic EcoRI restriction fragment length polymorphism (RFLP), may be associated with cancer susceptibility. In addition, this allele has also been linked to metastases and adverse survival in certain cancers, although studies of lung cancer patients from different populations have yielded controversial results. We studied 108 cases of surgical resected non-small-cell lung cancer (NSCLC) and found no evidence that MYCL genotypes were associated with tumour progression or a worse prognosis. However, the presence of loss of heterozygosity (LOH) at this chromosome 1p32 locus correlated significantly with regional lymph node involvement, as well as advanced TNM stage. These data indicate the existence of a chromosome 1p candidate tumour-suppressor gene(s), possibly in linkage disequilibrium with the EcoRI RFLP in specific populations, which appears to play a role in determining tumour progression in NSCLC. Refined mapping of the critical region of loss should help attempts to identify and clone the candidate gene.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8980399      PMCID: PMC2074830          DOI: 10.1038/bjc.1996.662

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  42 in total

1.  Correlation of L-myc genotypes to metastasis of gastric cancer and breast cancer.

Authors:  K Ishizaki; M Kato; M Ikenaga; K Honda; K Ozawa; J Toguchida
Journal:  J Natl Cancer Inst       Date:  1990-02-07       Impact factor: 13.506

2.  Amplification of protooncogenes in surgical specimens of human lung carcinomas.

Authors:  M Shiraishi; M Noguchi; Y Shimosato; T Sekiya
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

3.  Restriction fragment length polymorphism of the L-myc gene and susceptibility to metastasis in renal cancer patients.

Authors:  Y Kakehi; O Yoshida
Journal:  Int J Cancer       Date:  1989-03-15       Impact factor: 7.396

4.  Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.

Authors:  H Caron; P van Sluis; J de Kraker; J Bökkerink; M Egeler; G Laureys; R Slater; A Westerveld; P A Voûte; R Versteeg
Journal:  N Engl J Med       Date:  1996-01-25       Impact factor: 91.245

5.  Loss of heterozygosity of the L-myc oncogene in human breast tumors.

Authors:  I Bieche; M H Champeme; G Merlo; C J Larsen; R Callahan; R Lidereau
Journal:  Hum Genet       Date:  1990-06       Impact factor: 4.132

6.  Elevated frequency of a specific allele of the L-myc gene in male patients with bone and soft-tissue sarcomas.

Authors:  M Kato; J Toguchida; K Honda; M S Sasaki; M Ikenaga; M Sugimoto; T Yamaguchi; Y Kotoura; T Yamamuro; K Ishizaki
Journal:  Int J Cancer       Date:  1990-01-15       Impact factor: 7.396

7.  Cellular protoonocogenes are infrequently amplified in untreated non-small cell lung cancer.

Authors:  R J Slebos; S G Evers; S S Wagenaar; S Rodenhuis
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

8.  Restriction fragment length polymorphisms of L-myc and myb in human leukaemia and lymphoma in relation to age-selected controls.

Authors:  G Chenevix-Trench; M Southall; C Kidson
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

9.  Restriction fragment length polymorphism of the L-myc gene in oral cancer patients.

Authors:  D Saranath; R G Panchal; R Nair; A R Mehta; V Sanghavi; M G Deo
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

10.  Studies of the L-myc DNA polymorphism and relation to metastasis in Norwegian lung cancer patients.

Authors:  T Tefre; A L Børresen; S Aamdal; A Brøgger
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

View more
  5 in total

Review 1.  Molecular biology of lung cancer: clinical implications.

Authors:  Jill E Larsen; John D Minna
Journal:  Clin Chest Med       Date:  2011-10-07       Impact factor: 2.878

2.  TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma.

Authors:  Jau-Chen Lin; Yi-Ying Wu; Jing-Yi Wu; Tzu-Chieh Lin; Chen-Tu Wu; Yih-Leong Chang; Yuh-Shan Jou; Tse-Ming Hong; Pan-Chyr Yang
Journal:  EMBO Mol Med       Date:  2012-03-15       Impact factor: 12.137

3.  SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers.

Authors:  Corinna Altenberger; Gerwin Heller; Barbara Ziegler; Erwin Tomasich; Maximilian Marhold; Thais Topakian; Leonhard Müllauer; Petra Heffeter; György Lang; Adelheid End-Pfützenreuter; Balazs Döme; Britt-Madeleine Arns; Walter Klepetko; Christoph C Zielinski; Sabine Zöchbauer-Müller
Journal:  Mol Cancer       Date:  2017-01-05       Impact factor: 27.401

4.  MYCL promotes the progression of triple‑negative breast cancer by activating the JAK/STAT3 pathway.

Authors:  Hongnan Jiang; Xiaojun Li; Wei Wang; Yaofeng Hu; Dongliang Ren
Journal:  Oncol Rep       Date:  2022-09-30       Impact factor: 4.136

5.  Allelic imbalance and instability of microsatellite loci on chromosome 1p in human non-small-cell lung cancer.

Authors:  A V Gasparian; K K Laktionov; M S Belialova; N A Pirogova; A G Tatosyan; I B Zborovskaya
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.